Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors

Inclusion Criteria

• •Confirmed diagnosis of a solid malignancy with advanced disease that has relapsed, that is refractory to standard therapies, or for which there is not standard therapy, or for which the patient opts not to receive standard therapy.
• •At the recommended phase II dose level, triple-negative breast cancer defined as ER-negative, PR-negative, and HER2-negative, will be enrolled and another 10 patients with a solid malignancy who would benefit from a paclitaxel and carboplatin-based regimen, will also be enrolled.
• •Male or female ≥ 18 years of age
• •Able to swallow and retain oral medications